Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-α, and tegafur-uracil: a single-institution experience

Abstract

While the effectiveness of this immunochemotherapy resulted in a limited antitumor response, low-and intermediate-risk patients with metastatic RCC seemed likely to have a survival benefit. Patient selection is essential to enhance treatment efficiency and avoid useless treatment for high-risk patients.

Different responses to two types of 5-fluorouracil prodrugs in combination with interferon-alpha in pulmonary metastases of renal cell carcinoma: a case report

“…On June 2006, systemic examination demonstrated four coin lesions in bilateral lungs consistent with multiple pulmonary metastases of RCC without any other metastatic sites as shown in Figure 2 (A, D, G, J). He received combination therapy with IL-2, IFN-alpha (Sumiferon TM ), and UFT as reported previously [10]. It was discontinued immediately because of the skin toxicity due to IL-2.…”

Identification of a set of genes associated with response to interleukin-2 and interferon-α combination therapy for renal cell carcinoma through genome-wide gene expression profiling

“…monotherapy or combination therapy of interleukin (il)-2 and interferon (iFn)-α has been relatively widely applied for the treatment of advanced kidney cancers. In Japan, to reduce the risk of adverse reactions, the dose of il-2 is lower than that used in other countries (8)(9)(10)(11). While the response rate of monotherapy is as low as 10-20%, that of combination therapy is slightly better, 20-25% (12-17).…”

“…In Japan, to reduce the risk of adverse reactions, the dose of il-2 is lower than that used in other countries (8)(9)(10)(11). While the response rate of monotherapy is as low as 10-20%, that of combination therapy is slightly better, 20-25% (12)(13)(14)(15)(16)(17).…”